Literature DB >> 33860171

Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.

Jake E Payne1, Richard Chambers2, Paul Liknaitzky3,4.   

Abstract

Psychedelic and mindfulness interventions have been shown to improve mental ill-health and wellbeing, with a range of clinical processes and effects in common. However, each appear to contain specific challenges in the context of mental health treatment. In this Perspective, we focus on a set of distinct affordances, "useful differences", within psychedelic and mindfulness interventions that might address common challenges within the other intervention. Accordingly, we propose a set of applied synergies, indicating specific ways in which these two promising interventions might be combined for greater benefit. Metaphorically, on the journey toward mental health and wellbeing, we propose that psychedelic treatments may serve the role of Compass (initiating, motivating, and steering the course of mindfulness practice), with mindfulness interventions serving the role of Vehicle (integrating, deepening, generalizing, and maintaining the novel perspectives and motivation instigated by psychedelic experience). We outline a set of testable hypotheses and future research associated with the synergistic action of psychedelic and mindfulness interventions toward improved clinical outcomes.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33860171      PMCID: PMC8033772          DOI: 10.1021/acsptsci.1c00034

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  78 in total

1.  Adverse effects of meditation: a preliminary investigation of long-term meditators.

Authors:  D H Shapiro
Journal:  Int J Psychosom       Date:  1992

2.  Mindfulness-induced changes in gamma band activity - implications for the default mode network, self-reference and attention.

Authors:  Aviva Berkovich-Ohana; Joseph Glicksohn; Abraham Goldstein
Journal:  Clin Neurophysiol       Date:  2011-09-21       Impact factor: 3.708

Review 3.  Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.

Authors:  Frederick S Barrett; Roland R Griffiths
Journal:  Curr Top Behav Neurosci       Date:  2018

Review 4.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

5.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

6.  Open hearts build lives: positive emotions, induced through loving-kindness meditation, build consequential personal resources.

Authors:  Barbara L Fredrickson; Michael A Cohn; Kimberly A Coffey; Jolynn Pek; Sandra M Finkel
Journal:  J Pers Soc Psychol       Date:  2008-11

7.  Long-term follow-up of psilocybin-facilitated smoking cessation.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Roland R Griffiths
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-21       Impact factor: 3.829

8.  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Authors:  Rr Griffiths; Wa Richards; Mw Johnson; Ud McCann; R Jesse
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

Review 9.  Effectiveness of psychoeducation for depression: a systematic review.

Authors:  Mariana Flávia de Souza Tursi; Cristiane von Werne Baes; Fabio Ribeiro de Barros Camacho; Sandra Marcia de Carvalho Tofoli; Mario Francisco Juruena
Journal:  Aust N Z J Psychiatry       Date:  2013-06-05       Impact factor: 5.744

10.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Authors:  R L Carhart-Harris; M Bolstridge; C M J Day; J Rucker; R Watts; D E Erritzoe; M Kaelen; B Giribaldi; M Bloomfield; S Pilling; J A Rickard; B Forbes; A Feilding; D Taylor; H V Curran; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

View more
  5 in total

Review 1.  N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.

Authors:  Edward James; Joachim Keppler; Thomas L Robertshaw; Ben Sessa
Journal:  Hum Psychopharmacol       Date:  2022-02-17       Impact factor: 2.130

2.  Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.

Authors:  Otto Simonsson; Simon B Goldberg
Journal:  J Psychoactive Drugs       Date:  2022-01-09

3.  The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.

Authors:  Tomas Frymann; Sophie Whitney; David B Yaden; Joshua Lipson
Journal:  Front Psychol       Date:  2022-05-23

Review 4.  Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy.

Authors:  Agnieszka D Sekula; Luke Downey; Prashanth Puspanathan
Journal:  Front Psychol       Date:  2022-03-04

5.  Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees.

Authors:  Maggie Kamila Kiraga; Kim P C Kuypers; Malin Vedoy Uthaug; Johannes G Ramaekers; Natasha Leigh Mason
Journal:  Front Psychiatry       Date:  2022-07-07       Impact factor: 5.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.